Misha V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, Russia. Dr. Mikhail V. Blagosklonny subsequently immigrated to America, where he received the prestigious Fogarty Fellowship from the National Institutes of Health.
Within the period of his fellowship in Leonard Neckers’ laboratory at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Diverse biomedical topics, suchas targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last writer for a clinical phase I/II Trial publication.
After authoring seven papers during a brief yet resulting
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to team up with Tito Fojo. Together, they
Published 26 papers. In addition, Dr. Misha Blagosklonny published anumber of experimental research papers and theoretical articles as sole
Writer. Those sole-author publications
Included two crucial topics.
The first of these mentioned selectively killing cancer
Cells with deregulated cell cycle or drug resistance via
Verifying their resistance. The results and underlying
Notion were so revolutionary that they were inadequately cited by
Other scientists as “reversal of resistance, ” even though the publication was
Named, “Exploiting of drug resistance instead of its reversal. ” One major
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint paper in 2001.
The second topic throughout Dr. Blagosklonny’s sole-author articles
Is a research methodology to produce knowledge by
Bringing a few facts together from seemingly unrelated fields.
This results in new notions with testable forecasts, which in
Turn can be “tested” via analyzing the literature further. Once again, the
Concept was co-authored by Arthur Pardee in a 2002 publication in Nature. The
First success of the new research method was the description of the feedback
Regulation of p53, as supported by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Important result revealed by Dr.
Blagosklonny’s research methodology is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exclusively well-tolerated
Anti-aging drug, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny credit for
“connecting dots that others cannot even see. ”
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He went on to accept responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, before accepting another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
Since joining Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) by
Preventing body aging — in other words, “preventing cancer
Via staying young. ” His lab closely collaborated with
Andrei Gudkov’s and performed research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This led to the discovery of extra anti-aging
Medicines beyond rapamycin. The cell culture studies were
Complemented by studies in mice, including several models such as
Normal and aging mice, p53-deficient mice, and mice on a high-fat diet.
Dr. Misha Blagosklonny has also published extensively on the stoppage of cellular
Senescence by rapamycin and other mTOR inhibitors, life
Extension and cancer prevention in mice, and combinations of anti-
Aging medicines to be appliedamong humans. A
Rapamycin-based combination of seven clinically available medications has
Been named the “Koschei Formula” and is now utilized for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.
Mikhail V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, RUS. Dr. Misha V. Blagosklonny subsequently
Moved to America, where he received the prestigious Fogarty Fellowship from the National Institutes of Health.
Within the period of his fellowship in Leonard Neckers’ lab at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Different biomedical topics, like targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last writer for a clinical phase I/II Trial publication.
After authoring seven papers within the period of a brief yet fruitful
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to team up with Tito Fojo. Together, they
Published 26 papers. Moreover, Dr. Misha Blagosklonny published many of experimental research papers and theoretical articles as lead
Writer. These sole-author articles
Included two crucial themes.
The first of those discussed selectively killing cancer
Cells with deregulated cell cycle or drug resistance by
Validation their resistance. The outcomes and underlying
Concept were so revolutionary that they were incorrectly cited by
Other scientists as “reversal of resistance, ” even though the article was
Titled, “Exploiting of drug resistance instead of its reversal. ” One big
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.Blagosklonny co-authored a joint paper in 2001.
The second topic throughout Dr. Blagosklonny’s sole-author works
Is a research methodology to come up with knowledge by
Uniting a few facts together from seemingly unrelated areas.
This results in new notions containing testable forecasts, which in
Turn can be “tested” via analyzing the literature further. Likewise, the
Notion was co-authored by Arthur Pardee in a 2002 article in Nature. The
First success of the new research methodology was the description of the feedback
Regulation of p53, as supported by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Noticeable outcome revealed by Dr.
Blagosklonny’s research methodology is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exceptionally well-tolerated
Anti-aging medication, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny recognition for
“connecting dots that others can’t even see. ”
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He went on to accept responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, before receiving another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
Since joining Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) via
Stopping body aging — in other words, “preventing cancer
Via staying young. ” His laboratory closely worked together with
Andrei Gudkov’s and finalized research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This led to the discovery of extra anti-aging Medicines besides rapamycin. The cell culture studies were
Accompanied by studies in mice, including several models like
Normal and aging mice, p53-deficient mice, and mice on a high-fat diet.
Dr. Misha Blagosklonny has also published extensively on the prevention of cellular
Senescence via rapamycin and other mTOR inhibitors, life
Prolongation and cancer stoppage in mice, and combinations of anti-
Aging medications to be appliedamong humans. A
Rapamycin-based combination of seven clinically available drugs has
Been named the “Koschei Formula” and is now used for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.
